Children, adolescents, and adults aged aged 2 years or older who have mild to moderate atopic dermatitis (AD), persistent for more than 3 months, may be eligible for a 52-week research trial. Eligible participants having mild to moderate atopic dermatitis, with a diagnosis of AD for at least 3 months prior to screening, and no active or acute skin infections.
Participants will receive investigational topical treatment (active study drug) or placebo (inactive substance), via a cream. Study treatment and study-related assessments will be provided at no cost. Reimbursement for study-related expenses will be provided.
Study participation will last about 52 weeks and involve about 15 visits to the study centre.
The following information is from ClinicalTrials.gov
Last Update Posted: November 25, 2022
Ages Eligible for Study:
2 years and older
Sexes Eligible for Study:
Male and Female
Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.